

Curriculum Vitae

Personal information Katarina Dathe

Work experience

- Since 2019** Head of the Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Charité – Berlin Medical School
- 2014-2019** Senior research project leader (Human genetics/Pharmacology), Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Institute of Clinical Pharmacology and Toxicology, Charité – Berlin Medical School
- 2012-2014** Senior project leader, IGES Institute, Department Pharmaceutical Market, Berlin
- 2008-2011** Scientific associate, German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS), Berlin
- 2000-2008** Staff physician and research associate, Institute of Medical Genetics and Human Genetics, Charité – Berlin Medical School
- 2000** Resident, Clinic for Gynecology, Hospital Offenbach

Education and training

- 2010** Habilitation in Human Genetics, Charité – Berlin Medical School
- 2006** Board certification in Human Genetics, Berlin
- 2000** Medical doctor, University Mainz
- 1993-1998** University and medical school, Johannes-Gutenberg-University Mainz, 3rd state examination and licence as MD

Additional information

Publications

Selected publications

- Fietz A-K, Onken M, Padberg S, Schaefer C, **Dathe K**. Impact of maternal first trimester treatment regimen on the outcome of valproate exposed pregnancies: an observational Embryotox cohort study. *Sci Rep*. 2024; 14(1):674
- Onken M, Lohse L, Coulm B, Beghin D, Richardson JL, Bermejo-Sánchez E, Aguilera C, Bosch M, Cassina M, Chouchana L, De Santis M, Duman MK, Gören MZ, Johnson D, Bera APJ, Kaplan YC, Kennedy D, Kwok S, Lacroix I, Lepelley M, Pistelli A, Schaefer C, Te Winkel B, Uysal N, Winterfeld U, Yakuwa N, Diav-Citrin O, Vial T, **Dathe K**. Effects of maternal modafinil treatment on fetal development and neonatal growth parameters - a multicenter case series of the European Network of Teratology Information Services (ENTIS). *Acta Psychiatr Scand*. 2023; Dec 18. Online ahead of print
- Stegherr R, Beck E, Hultzs S, Schaefer C, **Dathe K**. Can non-responding mask or mimic drug effects on pregnancy outcome? Evaluation of case characteristics based on the national Embryotox cohort. *Reprod Toxicol*. 2022; 111:129-34
- Dathe K**, Frank J, Padberg S, Hultzs S, Beck E, Schaefer C. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort. *BMC Pregnancy and Childbirth*. 2022; 22(1):666
- Dathe K**, Hultzs S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. *Eur J Clin Pharmacol*. 2019;75(10):1347-53
- Dathe K**, Frank J, Padberg S, Hultzs S, Meixner K, Beck E, Meister R, Schaefer C. Negligible risk of prenatal ductus arteriosus closure or fetal renal impairment after third-trimester paracetamol use: evaluation of the German Embryotox cohort. *BJOG*. 2019;126(13):1560-7
- Dathe K**, Schaefer C. Drug safety in pregnancy: the German Embryotox Institute. *Eur J Clin Pharmacol*. 2018; 74(2):171-9

Projects

- Analyses (observational studies) on drug safety during pregnancy
- Evaluation and classification of birth defects
- Development of methods for analyzing drug-related adverse pregnancy outcomes

Memberships

Other Relevant Information